普拉洛芬联合典必殊治疗白内障患者术后炎症的临床效果研究  

Study on the clinical effect of pranoprofen combined with Dianbishu in the treatment of postoperative inflammation in cataract patients

作　　者：李颖颖 

机构地区：[1]辽宁省铁岭市爱尔眼科医院有限公司,112000

出　　处：《中国实用医药》2018年第4期73-75,共3页China Practical Medicine

摘　　要：目的分析普拉洛芬联合妥布霉素地塞米松滴眼液(典必殊)治疗白内障患者术后炎症的临床效果。方法 200例(226眼)进行白内障手术治疗的患者,随机分为典必殊组(100例,112眼)和联合用药组(100例,114眼)。典必殊组采用典必殊滴眼液,联合用药组采用普拉洛芬联合典必殊滴眼液。对两组患者的眼部症状及体征评分、黄斑中心凹厚度进行比较。结果术后1 d两组患者眼部症状及体征评分比较差异无统计学意义(P>0.05);术后1、2、4周联合用药组患者眼部症状及体征评分分别为(6.5±2.0)、(4.6±1.6)、(2.2±0.8)分,均显著低于典必殊组的(7.3±2.1)、(5.7±1.7)、(3.3±1.2)分,差异均具有统计学意义(P<0.05)。术后1 d、1周,两组患者黄斑中心凹厚度比较差异均无统计学意义(P>0.05);术后2、4周,联合用药组黄斑中心凹厚度分别为(236.8±14.9)、(237.1±15.4)μm,显著低于典必殊组的(245.8±12.6)、(252.4±9.9)μm,差异均具有统计学意义(P<0.05)。结论应用普拉洛芬联合典必殊治疗白内障患者术后炎症,可减轻患者眼部症状和体征,改善黄斑囊样水肿情况,临床效果显著,有利患者术后恢复,值得推广。Objective To analyze the clinical effect of pranoprofen combined with tobramycin dexamethasone eye drops （Dianbishu） in the treatment of postoperative inflammation in cataract patients. Methods A total of 200 patients （226 eyes） with cataract surgery were randomly divided into Dianbishu group （100 eases, 112 eyes ）and combined group （100 cases, 114 cases）. Dianbishu group received Dianbishu eye drops, and combined group received pranoprofen combined with Dianbishu eye drops. Comparison were made on ocular symptoms and signs score, macular fovea thickness between the two groups. Results In postoperative 1 d, both groups had no statistically significant difference in ocular symptoms and signs score （P〉0.05）. In postoperative 1, 2 and 4 weeks, the combined group had obviously lower ocular symptoms and signs score respectively as （6.5±2.0）, （4.6 ± 1.6） and （2.2± 0.8） points than （7.3 ± 2.1）, （5.7 ±1.7） and （3.3 ± 1.2） points in Dianbishu group, and their difference was statistically significant （P〈0.05）. In postoperative 1 d and 1 week, both groups had no statistically significant difference in maeular fovea thickness （P〉0.05）. In postoperative 2 and 4 weeks, the combined group had obviously lower macular fovea thickness respectively as （236.8 ± 14.9） and （237.1 ±15.4） μm than （245.8±12.6） and （252.4±9.9） μm in Dianbishu group, and their difference was statistically significant （P〈0.05）. Conclusion Application of pranoprofen and Dianbishu in treating postoperative inflammation of cataract patients shows remarkable clinical effect in reducing ocular symptoms and signs score and improve macular fovea thickness. It is beneficial for postoperative recovery of patients. It is worth popularizing.

关 键 词：白内障 术后炎症 普拉洛芬 妥布霉素地塞米松滴眼液 黄斑水肿 

分 类 号：R779.6[医药卫生—眼科]